Papillomaviruses as targets for cancer gene therapy

Cancer Gene Therapy

Volumn 13, Issue 5, 2006, Pages 445-450

  Shillitoe, E J ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cervical cancer; Gene therapy; Oral cancer; Papillomaviruses; Review

Indexed keywords

ADENOVIRUS VECTOR; ADENYLATE CYCLASE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CANCER VACCINE; COMPLEMENTARY RNA; PLASMID VECTOR; PROTEIN P53; RIBOZYME; SMALL INTERFERING RNA; VIRUS VECTOR; WART VIRUS VACCINE;

CANCER; CANCER PREVENTION; CANCER THERAPY; CHROMOSOME DAMAGE; CLINICAL TRIAL; DOWN REGULATION; DRUG TARGETING; GENE DELETION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; MALIGNANT TRANSFORMATION; MOUTH CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; UPREGULATION; UTERINE CERVIX CANCER; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS TYPING; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; FEMALE; GENE THERAPY; HUMANS; MOUTH NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

ADENOVIRIDAE; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRIDAE;

EID: 33645893204     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700926     Document Type: Review

References (54)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2002; 2: 342-350.
2. Rous P, Beard J. Progression to carcinoma of virus-induced rabbit papillomas. J Exp Med 1935; 62: 523-545.
3. Gissmann L, zur Hausen H. Partial characterization of viral DNA from human genital warts. Int J Cancer 1980; 25: 605-609.
4. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78: 11451-11460.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
6. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-280.
7. Miller C, Johnstone B. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 2001; 91: 622-635.
8. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P et al. Human papillomavirus and oral cancer; the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-1783.
9. Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A et al. Cancer statistics. CA Cancer J Clin 2005; 55: 10-30.
10. Truman BI, Gooch BF, Sulemana I, Gift HC, Horowitz AM, Evans CA et al. Reviews of evidence on interventions to prevent dental caries, oral and pharyngeal cancers, and sports-related craniofacial injuries. Am J Prev Med 2002; 23: 21.
11. Shillitoe EJ, Kamath P, Chen Z. Papillomaviruses as targets for cancer gene therapy. In: Sobol R, Scanlon K (eds). The Internet Book of Gene Therapy. Stamford: Appleton and Lange, 1995, pp. 269-280.
12. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
13. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and SV40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 1990; 9: 153-160.
14. Scheffner M, Munger K, Huibregtse JM, Howley PM. Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J 1992; 11: 2425-2431.
15. Shin KH, Tannyhill RJ, Liu X, Park NH. Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells. Oncogene 1996; 12: 1089-1096.
16. Veeraraghavalu K, Pedtt M, Kumar RV, Nair P, Rangarajan A, Stanley MA et al. Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in Jagged1 and Manic Fringe Expression linked to Notch activation. J Virol 2004; 78: 8687-8700.
17. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001; 93: 232-235.
18. Dai M, Clifford GM, le Calvez F, Castellsague X, Snijders PJ, Pawlita M et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 2004; 64: 468-471.
19. Wiest T, Schwartz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRB cell cycle control. Oncogene 2002; 21: 1510-1517.
20. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004; 96: 998-1006.
21. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
22. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-1765.
23. MacKenzie D. Will cancer vaccine get to all women? New Sci 2005; 186: 8.
24. Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncogene. Cancer Res 2005; 65: 641-649.
25. Goodwin EC, Naeger LK, Breiding DE, Androphy EJ, DiMaio D. Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J Virol 1998; 72: 3925-3934.
26. Francis DA, Schmid SI, Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 2000; 74: 2679-2686.
27. Shillitoe EJ, Noonan S. Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol 2000; 36: 214-220.
28. Shillitoe EJ, Lou E, Griffith C. A herpes/papillomavirus chimera for treatment of oral cancer. J Dent Res 2005; 84 (Special Issue A): Abstract 1403.
29. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988; 48: 3780-3786.
30. Steele C, Sacks PG, Adler-Storthz K, Shillitoe EJ. Effects on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res 1992; 52: 4706-4711.
31. Steele C, Cowsert LM, Shillitoe EJ. Effects of human papillomavirus type-18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res 1993; 53: 2330-2337.
32. Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Penalver M et al. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol 1997; 64: 18-25.
33. He Y, Huang L. Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter. Cancer Res 1997; 57: 3993-3999.
34. Hamada K, Sakaue M, Alemany R, Zhang WW, Horio Y, Roth JA et al. Adenovirus-mediated transfer of HPV E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996; 63: 219-227.
35. Choo CK, Ling MT, Suen CK, Chan KW, Kwong YL. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol Oncol 2000; 78: 293-301.
36. Chen Z, Kamath P, Zhang S, Weil MM, Shillitoe EJ. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther 1995; 2: 263-271.
37. Chen Z, Kamath P, Zhang S, St John L, Adler-Storthz K, Shillitoe EJ. Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther 1996; 3: 18-23.
38. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A, DiPaolo JA. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci USA 1998; 95: 1189-1194.
39. Pan W, Xin P, Morrey J, Clawson GA. A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and Hepatitis B virus. Mol Ther 2004; 9: 596-606.
40. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002; 21: 6041-6048.
41. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-5945.
42. Koivusalo R, Krausz E, Helenius H, Hietanen S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA. Opposite effect of siRNA in combination with different drugs. Mol Pharmacol 2005; 68: 372-382.
43. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003; 8: 762-768.
44. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000; 97: 6693-6697.
45. Braun K, Ehemann V, Waldeck W, Pipkorn R, Corban-Wilhelm H, Jenne J et al. HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). Cancer Lett 2004; 209: 37-49.
46. Ahn WS, Han YJ, Bae SM, Kim TH, Rho MS, Lee JM et al. Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line. Jap J Cancer Res 2002; 93: 1012-1019.
47. Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S et al. Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995; 2: 105-111.
48. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-3667.
49. McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumor-suppressor genes. Gene Therapy 2004; 11: 497-503.
50. Balague C, Noya F, Alemany R, Chow LT, Curiel DT. Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J Virol 2001; 75: 7602-7611.
51. Shillitoe EJ, Noonan S, Hinkle CC, Marini FC, Kellman RM. Transduction of normal and malignant oral epithelium by particle bombardment. Cancer Gene Ther 1998; 5: 176-182.
52. Piro LD. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology 2004; 18 (Suppl 10): 5-10.
53. Kunke D, Grimm D, Denger S, Kreuzer J, Delius H, Komitowski D et al. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther 2000; 7: 766-777.
54. Walz CM, Correa-Ochoa MM, Muller M, Schlehofer JR. Adenoassociated virus type 2-induced inhibition of the human papillomavirus type 18 promoter in transgenic mice. Virol 2002; 293: 172-181.